Login to Your Account



Summit Sells Dextra Lab Unit, Now Has Funds to Stay Afloat

By Nuala Mora


Wednesday, September 9, 2009
LONDON - Summit Corp. plc completed the life-saving divestment of its services businesses, selling its Dextra Laboratories subsidiary to New Zealand Pharmaceuticals for £950,000 (US$1.6 million). (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription